- Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients
-
Kim H, Kang HJ, Park KD, Koh KN, Im HJ, Seo JJ, Lee JW, Chung NG, Cho B, Kim HK, Lee JM, Hah JO, Lee JA, Lee YH, Park SK, Baek HJ, Kook H, Kim JY, Kim HS, Kim HM, Chueh HW, Park M, Yoon HS, Lee MJ, Choi HS, Ahn HS, Kawano Y, Park JW, Hahn S, Shin HY
- KMID: 2437626
- Cancer Res Treat.
- 2019 Jan;51(1):357-367.
- doi: 10.4143/crt.2017.457
PURPOSE: Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
-
Kim IH, Lee JE, Youn HJ, Song BJ, Chae BJ
- KMID: 2379402
- J Breast Cancer.
- 2017 Mar;20(1):82-90.
- doi: 10.4048/jbc.2017.20.1.82
PURPOSE: We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment. METHODS: The medical records of 228 patients who underwent... -
- CITED
-
- Close
- SHARE
-
- Close
- Myocardial Protective Effect of Cardioxane for the Myocardial Damage due to Doxorubicin
-
Park HJ, Oh JM, Kim SH, Lee CH, Kim SS
- KMID: 1607033
- J Korean Pediatr Soc.
- 2003 Sep;46(9):876-882.
PURPOSE: To find out the myocardial protective effect of cardioxane for the myocardial damage by doxorubicin. METHODS: Using Eighteen rabbits(2.0-3.2 kg), doxorubicin(30 mg/m2) was injected intravenously once a week in group... -
- CITED
-
- Close
- SHARE
-
- Close
